- Cytokeratin 13
Cytokeratin 13Catalog number: CK113
Cytokeratin 13 is an acidic filament protein, which especially exprimed in squamous epithelia. Therefore it is found in exocervix, vagina, oral mucosa, tongue, oesophage, epidermis and urothelium. The CK13 antibody mainly reacts with squamous epithelia and squamous cell carcinoma. Cytokeratins are a group of water soluble filament proteins, which are components of the cytoskeleton of the epidermis and other epithelial cells. Gel-electrophoretic investigation revealed 20 different Cytokeratins, characterised by different molecular sizes and pI-values. They can be subdivided into basic and acid subfamilies. The nomenclature according to Moll et al. (1982) is most commonly used. Acid Cytokeratin 13, 54 kD, pI 5.1.
Immunogen: Human purified Cytokeratin 13
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 50 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if further dilution is required.
Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 50 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if further dilution is required.
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Species Reactivity: Human, cattle, rat
Incubation Time: 60 min at RT
Working Concentration: (liquid conc.) neat
Pre-Treatment: Improvement of staining with Unmasking Fluid G (Art. No. DE007) or Unmasking Fluid C (Art. No. DE000)
Positive Control: Urothelial carcinoma
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Moll R., Franke W.W., Schiller D.L., Geiger B., and Krepler R. (1982) The Catalog of Human Cytokeratins: Patterns of Expression in Normal Epithelia, Tumors and Cultured Cells. Cell 31; 11 ff. 2. Sun T.-T. Tseng S.C.G., Huang A.J.W., Cooper D., Lynch M.H., Weiss R., Eichner R., and Schermer (1985) Monoclonal antibody studies of keratin expression: A review. In: Intermediate Filaments , Wang E. et al. eds. N.Y. Acad. Sci. 455, pp 307 ff. 3. Petzoldt JL, Leigh IM, Duffy PG, Masters JR (1994) Culture and characterisation of human urothelium in vivo and in vitro. Urol Res;22(2):67-74 4. Rugg E, Magee G, Wilson N, Brandrup F, Hamburger J, Lane E (1999) Identification of two novel mutations in keratin 13 as the cause of white sponge naevus. Oral Dis 5(4):321-324. 5. De La Rosette J., Smedts F., Schoots C., Hoek H., and P. Laguna (2002) Changing patterns of keratin expression could be associated with functional maturation of the developing human bladder. J. Urol. 168(2); 709-717.
Safety Datasheet(s) for this product: